Flexion Therapeutics Inc. (FLXN) Stock Price Down 3.6%
Flexion Therapeutics Inc. (NASDAQ:FLXN) was down 3.6% on Wednesday . The company traded as low as $17.07 and last traded at $17.33, with a volume of 150,449 shares. The stock had previously closed at $17.97.
A number of equities research analysts have recently weighed in on FLXN shares. Wells Fargo & Co. started coverage on shares of Flexion Therapeutics in a report on Tuesday, May 3rd. They issued an “outperform” rating for the company. BMO Capital Markets started coverage on shares of Flexion Therapeutics in a report on Tuesday, June 28th. They issued an “outperform” rating and a $35.00 price objective for the company. Cantor Fitzgerald restated a “buy” rating on shares of Flexion Therapeutics in a report on Saturday, May 14th. Royal Bank Of Canada restated a “buy” rating on shares of Flexion Therapeutics in a report on Thursday, June 30th. Finally, Zacks Investment Research lowered shares of Flexion Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, May 17th. Nine investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $33.17.
The company’s market cap is $464.28 million. The stock’s 50-day moving average price is $15.91 and its 200 day moving average price is $12.76.
Flexion Therapeutics (NASDAQ:FLXN) last announced its quarterly earnings data on Wednesday, August 3rd. The specialty pharmaceutical company reported ($0.63) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.04. On average, analysts predict that Flexion Therapeutics Inc. will post ($2.69) earnings per share for the current year.
In other Flexion Therapeutics news, Director Samuel D. Colella bought 25,504 shares of the business’s stock in a transaction that occurred on Tuesday, June 21st. The stock was purchased at an average cost of $13.71 per share, with a total value of $349,659.84. Following the completion of the acquisition, the director now owns 3,435 shares in the company, valued at approximately $47,093.85. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Samuel D. Colella bought 714,285 shares of the business’s stock in a transaction that occurred on Wednesday, June 8th. The stock was acquired at an average cost of $14.00 per share, with a total value of $9,999,990.00. The disclosure for this purchase can be found here.
Other hedge funds and institutional investors have bought and sold shares of the company. Jennison Associates LLC raised its position in Flexion Therapeutics by 2.7% in the fourth quarter. Jennison Associates LLC now owns 2,907,755 shares of the specialty pharmaceutical company’s stock worth $56,032,000 after buying an additional 76,487 shares during the period. Schroder Investment Management Group raised its position in Flexion Therapeutics by 21.0% in the fourth quarter. Schroder Investment Management Group now owns 470,200 shares of the specialty pharmaceutical company’s stock worth $9,061,000 after buying an additional 81,500 shares during the period. Finally, Wells Fargo & Company MN raised its position in Flexion Therapeutics by 16.2% in the fourth quarter. Wells Fargo & Company MN now owns 430,545 shares of the specialty pharmaceutical company’s stock worth $8,296,000 after buying an additional 59,866 shares during the period.
Flexion Therapeutics, Inc is a specialty pharmaceutical company. The Company is focused on the development and commercialization of therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis and post-operative pain. The Company’s portfolio of product candidates addresses the OA pain treatment spectrum, from moderate to severe pain.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.